Menu
Menu
Just as the assessment is an important part of Psychedelic-Assisted Psychotherapy (PAP), the integration after PAP treatment is even more important.
Several key elements are involved in strategic integration in an attempt to avoid influencing or fulfilling the therapist’s agenda above what is important to the patient.
Ketamine has been used legally for depression, anxiety, and a host of other mental health conditions. This recording reviews the key elements of integration strategies specific to the mental health condition being addressed. Ketamine treatment has some specific nuances that will be outlined and compared to other psychedelics.
Ways to improve the efficacy of the integration are described with specific case examples to highlight tools to improve outcome.
Viewers will leave with an understanding as to when ketamine assisted psychotherapy might be beneficial to specific patients.
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1 hours CPD for points calculation by your association.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice (5.78 MB) | 58 Pages | Available after Purchase | |
| Text Document | Transcript (36.9 KB) | 13 Pages | Available after Purchase |
| Manual - The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice - French (5.78 MB) | 58 Pages | Available after Purchase | |
| Text Document | Transcript - French (36.9 KB) | 13 Pages | Available after Purchase |
| Manual - The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice - Italian (5.78 MB) | 58 Pages | Available after Purchase | |
| Text Document | Transcript - Italian (36.9 KB) | 13 Pages | Available after Purchase |
Phil Wolfson, MD, is president and CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Center. Phil’s book, The Ketamine Papers, is the seminal work in the burgeoning ketamine arena. He is principal investigator for the MAPS sponsored Phase 2, the FDA-approved 18-person study of MDMA-Assisted Psychotherapy for individuals with significant anxiety due to life threatening illnesses. His clinical practice with ketamine has informed his leadership role in the development of Ketamine-Assisted Psychotherapy.
Speaker Disclosures:
Financial: Philip Wolfson is the founder and CEO of The Ketamine Research Foundation. He has an ownership interest in Progressive Therapeutics, Inc. Dr. Wolfson will address off-label uses. He has no relevant financial relationships with ineligible organizations.
Non-financial: Philip Wolfson has no relevant non-financial relationship to disclose.
Please wait ...